CARGO Therapeutics, Inc. announced the discontinuation of its FIRCE-1 Phase 2 clinical study of firicabtagene autoleucel (firi-cel) for large B-cell lymphoma due to safety concerns and ...
CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a competitive benefit-risk profile for patients.
NEW YORK, NY / ACCESS Newswire / March 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO ...
LOS ANGELES, CA / ACCESS Newswire / March 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...
Hosted on MSN1mon
Cargo Therapeutics stock tumbles after trial setbackCARGO Therapeutics, which specializes in developing cell therapies for cancer, elected to halt the FIRCE-1 study of firi-cel for patients with large B-cell lymphoma after an ad hoc analysis ...
CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company advancing next generation, potentially curative cell therapies for cancer patients, today announced that it has elected ...
CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a competitive benefit-risk profile for patients.
CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel) 1; Company believes results do not support a competitive benefit-risk profile for patients. CARGO ...
CARGO intends to present an analysis of the FIRCE-1 Phase 2 study at a future medical conference. CARGO Therapeutics, Inc. is a clinical-stage biotechnology company advancing next-generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback